4D pharma plc
4D pharma plc (LBPS) Stock Competitors & Peer Comparison
See (LBPS) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| LBPS | $1.65 | +0.00% | 0 | N/A | N/A | N/A |
| VRTX | $395.12 | -0.59% | 101.2B | 28.05 | $14.07 | N/A |
| REGN | $589.48 | -1.45% | 61.4B | 14.86 | $39.66 | +0.45% |
| ALNY | $454.38 | -2.82% | 59.6B | -184.02 | -$2.47 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ARGX | $660.00 | -0.56% | 40.4B | 33.59 | $19.65 | N/A |
| BNTX | $110.88 | +0.10% | 26.7B | -66.80 | -$1.66 | N/A |
| BGNE | $184.71 | +0.49% | 20.2B | -22.55 | -$8.19 | N/A |
| SMMT | $26.20 | +0.73% | 19.5B | -25.94 | -$1.01 | N/A |
| DNA-WT | $0.27 | -2.76% | 18.7B | N/A | N/A | N/A |
Stock Comparison
LBPS vs VRTX Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, VRTX has a market cap of 101.2B. Regarding current trading prices, LBPS is priced at $1.65, while VRTX trades at $395.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas VRTX's P/E ratio is 28.05. In terms of profitability, LBPS's ROE is -1.06%, compared to VRTX's ROE of +0.22%. Regarding short-term risk, LBPS is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for LBPS.Check VRTX's competition here
LBPS vs REGN Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, REGN has a market cap of 61.4B. Regarding current trading prices, LBPS is priced at $1.65, while REGN trades at $589.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas REGN's P/E ratio is 14.86. In terms of profitability, LBPS's ROE is -1.06%, compared to REGN's ROE of +0.15%. Regarding short-term risk, LBPS is less volatile compared to REGN. This indicates potentially lower risk in terms of short-term price fluctuations for LBPS.Check REGN's competition here
LBPS vs ALNY Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, ALNY has a market cap of 59.6B. Regarding current trading prices, LBPS is priced at $1.65, while ALNY trades at $454.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas ALNY's P/E ratio is -184.02. In terms of profitability, LBPS's ROE is -1.06%, compared to ALNY's ROE of -2.74%. Regarding short-term risk, LBPS is less volatile compared to ALNY. This indicates potentially lower risk in terms of short-term price fluctuations for LBPS.Check ALNY's competition here
LBPS vs SGEN Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, LBPS is priced at $1.65, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas SGEN's P/E ratio is -57.19. In terms of profitability, LBPS's ROE is -1.06%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, LBPS is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for LBPS.Check SGEN's competition here
LBPS vs ARGX Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, ARGX has a market cap of 40.4B. Regarding current trading prices, LBPS is priced at $1.65, while ARGX trades at $660.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas ARGX's P/E ratio is 33.59. In terms of profitability, LBPS's ROE is -1.06%, compared to ARGX's ROE of +0.26%. Regarding short-term risk, LBPS is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for LBPS.Check ARGX's competition here
LBPS vs BNTX Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, BNTX has a market cap of 26.7B. Regarding current trading prices, LBPS is priced at $1.65, while BNTX trades at $110.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas BNTX's P/E ratio is -66.80. In terms of profitability, LBPS's ROE is -1.06%, compared to BNTX's ROE of -0.02%. Regarding short-term risk, LBPS is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for LBPS.Check BNTX's competition here
LBPS vs BGNE Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, LBPS is priced at $1.65, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas BGNE's P/E ratio is -22.55. In terms of profitability, LBPS's ROE is -1.06%, compared to BGNE's ROE of -0.05%. Regarding short-term risk, LBPS is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for LBPS.Check BGNE's competition here
LBPS vs SMMT Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, SMMT has a market cap of 19.5B. Regarding current trading prices, LBPS is priced at $1.65, while SMMT trades at $26.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas SMMT's P/E ratio is -25.94. In terms of profitability, LBPS's ROE is -1.06%, compared to SMMT's ROE of -2.09%. Regarding short-term risk, LBPS is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for LBPS.Check SMMT's competition here
LBPS vs DNA-WT Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, LBPS is priced at $1.65, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, LBPS's ROE is -1.06%, compared to DNA-WT's ROE of -0.45%. Regarding short-term risk, LBPS is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for LBPS.Check DNA-WT's competition here
LBPS vs INCY Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, INCY has a market cap of 16.6B. Regarding current trading prices, LBPS is priced at $1.65, while INCY trades at $85.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas INCY's P/E ratio is 20.10. In terms of profitability, LBPS's ROE is -1.06%, compared to INCY's ROE of +0.24%. Regarding short-term risk, LBPS is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for LBPS.Check INCY's competition here
LBPS vs RPRX Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, RPRX has a market cap of 15.7B. Regarding current trading prices, LBPS is priced at $1.65, while RPRX trades at $36.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas RPRX's P/E ratio is 15.86. In terms of profitability, LBPS's ROE is -1.06%, compared to RPRX's ROE of +0.15%. Regarding short-term risk, LBPS is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for LBPS.Check RPRX's competition here
LBPS vs GMAB Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, GMAB has a market cap of 15.6B. Regarding current trading prices, LBPS is priced at $1.65, while GMAB trades at $24.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas GMAB's P/E ratio is 12.77. In terms of profitability, LBPS's ROE is -1.06%, compared to GMAB's ROE of +0.28%. Regarding short-term risk, LBPS is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for LBPS.Check GMAB's competition here
LBPS vs UTHR Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, UTHR has a market cap of 14.1B. Regarding current trading prices, LBPS is priced at $1.65, while UTHR trades at $312.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas UTHR's P/E ratio is 12.18. In terms of profitability, LBPS's ROE is -1.06%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, LBPS is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for LBPS.Check UTHR's competition here
LBPS vs KRTX Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, LBPS is priced at $1.65, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas KRTX's P/E ratio is -28.09. In terms of profitability, LBPS's ROE is -1.06%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, LBPS is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for LBPS.Check KRTX's competition here
LBPS vs ASND Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, ASND has a market cap of 11.8B. Regarding current trading prices, LBPS is priced at $1.65, while ASND trades at $194.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas ASND's P/E ratio is -36.83. In terms of profitability, LBPS's ROE is -1.06%, compared to ASND's ROE of +1.52%. Regarding short-term risk, LBPS is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for LBPS.Check ASND's competition here
LBPS vs BMRN Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, BMRN has a market cap of 11.2B. Regarding current trading prices, LBPS is priced at $1.65, while BMRN trades at $58.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas BMRN's P/E ratio is 17.28. In terms of profitability, LBPS's ROE is -1.06%, compared to BMRN's ROE of +0.11%. Regarding short-term risk, LBPS is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for LBPS.Check BMRN's competition here
LBPS vs MRNA Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, MRNA has a market cap of 10.6B. Regarding current trading prices, LBPS is priced at $1.65, while MRNA trades at $27.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas MRNA's P/E ratio is -3.61. In terms of profitability, LBPS's ROE is -1.06%, compared to MRNA's ROE of -0.27%. Regarding short-term risk, LBPS is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for LBPS.Check MRNA's competition here
LBPS vs EXEL Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, EXEL has a market cap of 10.4B. Regarding current trading prices, LBPS is priced at $1.65, while EXEL trades at $38.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas EXEL's P/E ratio is 18.57. In terms of profitability, LBPS's ROE is -1.06%, compared to EXEL's ROE of +0.28%. Regarding short-term risk, LBPS is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for LBPS.Check EXEL's competition here
LBPS vs RXDX Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, LBPS is priced at $1.65, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas RXDX's P/E ratio is -56.47. In terms of profitability, LBPS's ROE is -1.06%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, LBPS is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for LBPS.Check RXDX's competition here
LBPS vs BBIO Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, BBIO has a market cap of 9.4B. Regarding current trading prices, LBPS is priced at $1.65, while BBIO trades at $49.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas BBIO's P/E ratio is -11.88. In terms of profitability, LBPS's ROE is -1.06%, compared to BBIO's ROE of +0.51%. Regarding short-term risk, LBPS is less volatile compared to BBIO. This indicates potentially lower risk in terms of short-term price fluctuations for LBPS.Check BBIO's competition here
LBPS vs MDGL Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, MDGL has a market cap of 9.2B. Regarding current trading prices, LBPS is priced at $1.65, while MDGL trades at $414.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas MDGL's P/E ratio is -32.78. In terms of profitability, LBPS's ROE is -1.06%, compared to MDGL's ROE of -0.38%. Regarding short-term risk, LBPS is less volatile compared to MDGL. This indicates potentially lower risk in terms of short-term price fluctuations for LBPS.Check MDGL's competition here
LBPS vs VRNA Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, VRNA has a market cap of 9B. Regarding current trading prices, LBPS is priced at $1.65, while VRNA trades at $105.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas VRNA's P/E ratio is -101.50. In terms of profitability, LBPS's ROE is -1.06%, compared to VRNA's ROE of -0.39%. Regarding short-term risk, LBPS is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for LBPS.Check VRNA's competition here
LBPS vs TECH Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, TECH has a market cap of 8.9B. Regarding current trading prices, LBPS is priced at $1.65, while TECH trades at $57.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas TECH's P/E ratio is 124.11. In terms of profitability, LBPS's ROE is -1.06%, compared to TECH's ROE of +0.06%. Regarding short-term risk, LBPS is less volatile compared to TECH. This indicates potentially lower risk in terms of short-term price fluctuations for LBPS.Check TECH's competition here
LBPS vs IMGN Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, LBPS is priced at $1.65, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas IMGN's P/E ratio is -111.55. In terms of profitability, LBPS's ROE is -1.06%, compared to IMGN's ROE of -1.43%. Regarding short-term risk, LBPS is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for LBPS.Check IMGN's competition here
LBPS vs HALO Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, HALO has a market cap of 8.4B. Regarding current trading prices, LBPS is priced at $1.65, while HALO trades at $71.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas HALO's P/E ratio is 16.43. In terms of profitability, LBPS's ROE is -1.06%, compared to HALO's ROE of +1.37%. Regarding short-term risk, LBPS is less volatile compared to HALO. This indicates potentially lower risk in terms of short-term price fluctuations for LBPS.Check HALO's competition here
LBPS vs BPMC Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, LBPS is priced at $1.65, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas BPMC's P/E ratio is -51.58. In terms of profitability, LBPS's ROE is -1.06%, compared to BPMC's ROE of -0.49%. Regarding short-term risk, LBPS is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for LBPS.Check BPMC's competition here
LBPS vs CERE Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, LBPS is priced at $1.65, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas CERE's P/E ratio is -16.47. In terms of profitability, LBPS's ROE is -1.06%, compared to CERE's ROE of -0.72%. Regarding short-term risk, LBPS is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for LBPS.Check CERE's competition here
LBPS vs ROIV Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, ROIV has a market cap of 8.1B. Regarding current trading prices, LBPS is priced at $1.65, while ROIV trades at $11.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas ROIV's P/E ratio is -10.94. In terms of profitability, LBPS's ROE is -1.06%, compared to ROIV's ROE of -0.10%. Regarding short-term risk, LBPS is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for LBPS.Check ROIV's competition here
LBPS vs ROIVW Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, ROIVW has a market cap of 7.8B. Regarding current trading prices, LBPS is priced at $1.65, while ROIVW trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas ROIVW's P/E ratio is -0.67. In terms of profitability, LBPS's ROE is -1.06%, compared to ROIVW's ROE of -0.10%. Regarding short-term risk, LBPS is less volatile compared to ROIVW. This indicates potentially lower risk in terms of short-term price fluctuations for LBPS.Check ROIVW's competition here
LBPS vs JAZZ Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, JAZZ has a market cap of 7.5B. Regarding current trading prices, LBPS is priced at $1.65, while JAZZ trades at $123.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas JAZZ's P/E ratio is -17.64. In terms of profitability, LBPS's ROE is -1.06%, compared to JAZZ's ROE of -0.10%. Regarding short-term risk, LBPS is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for LBPS.Check JAZZ's competition here
LBPS vs CORT Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, CORT has a market cap of 7.4B. Regarding current trading prices, LBPS is priced at $1.65, while CORT trades at $70.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas CORT's P/E ratio is 62.79. In terms of profitability, LBPS's ROE is -1.06%, compared to CORT's ROE of +0.20%. Regarding short-term risk, LBPS is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for LBPS.Check CORT's competition here
LBPS vs RVMD Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, RVMD has a market cap of 6.9B. Regarding current trading prices, LBPS is priced at $1.65, while RVMD trades at $37.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas RVMD's P/E ratio is -8.19. In terms of profitability, LBPS's ROE is -1.06%, compared to RVMD's ROE of -0.42%. Regarding short-term risk, LBPS is less volatile compared to RVMD. This indicates potentially lower risk in terms of short-term price fluctuations for LBPS.Check RVMD's competition here
LBPS vs RYTM Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, RYTM has a market cap of 6.9B. Regarding current trading prices, LBPS is priced at $1.65, while RYTM trades at $103.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas RYTM's P/E ratio is -34.31. In terms of profitability, LBPS's ROE is -1.06%, compared to RYTM's ROE of -1.55%. Regarding short-term risk, LBPS is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for LBPS.Check RYTM's competition here
LBPS vs IONS Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, IONS has a market cap of 6.8B. Regarding current trading prices, LBPS is priced at $1.65, while IONS trades at $42.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas IONS's P/E ratio is -24.26. In terms of profitability, LBPS's ROE is -1.06%, compared to IONS's ROE of -0.45%. Regarding short-term risk, LBPS is less volatile compared to IONS. This indicates potentially lower risk in terms of short-term price fluctuations for LBPS.Check IONS's competition here
LBPS vs RETA Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, LBPS is priced at $1.65, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas RETA's P/E ratio is -66.29. In terms of profitability, LBPS's ROE is -1.06%, compared to RETA's ROE of +0.47%. Regarding short-term risk, LBPS is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for LBPS.Check RETA's competition here
LBPS vs RNA Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, RNA has a market cap of 6B. Regarding current trading prices, LBPS is priced at $1.65, while RNA trades at $46.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas RNA's P/E ratio is -13.02. In terms of profitability, LBPS's ROE is -1.06%, compared to RNA's ROE of -0.33%. Regarding short-term risk, LBPS is less volatile compared to RNA. This indicates potentially lower risk in terms of short-term price fluctuations for LBPS.Check RNA's competition here
LBPS vs AXSM Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, AXSM has a market cap of 5.9B. Regarding current trading prices, LBPS is priced at $1.65, while AXSM trades at $118.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas AXSM's P/E ratio is -23.37. In terms of profitability, LBPS's ROE is -1.06%, compared to AXSM's ROE of -3.58%. Regarding short-term risk, LBPS and AXSM have similar daily volatility (2.45).Check AXSM's competition here
LBPS vs ABVX Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, ABVX has a market cap of 5.8B. Regarding current trading prices, LBPS is priced at $1.65, while ABVX trades at $77.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas ABVX's P/E ratio is -22.53. In terms of profitability, LBPS's ROE is -1.06%, compared to ABVX's ROE of -1.62%. Regarding short-term risk, LBPS is less volatile compared to ABVX. This indicates potentially lower risk in terms of short-term price fluctuations for LBPS.Check ABVX's competition here
LBPS vs ABCM Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, LBPS is priced at $1.65, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, LBPS's ROE is -1.06%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, LBPS is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for LBPS.Check ABCM's competition here
LBPS vs ISEE Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, LBPS is priced at $1.65, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas ISEE's P/E ratio is -22.44. In terms of profitability, LBPS's ROE is -1.06%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, LBPS is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for LBPS.Check ISEE's competition here
LBPS vs NUVL Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, NUVL has a market cap of 5.5B. Regarding current trading prices, LBPS is priced at $1.65, while NUVL trades at $76.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas NUVL's P/E ratio is -15.46. In terms of profitability, LBPS's ROE is -1.06%, compared to NUVL's ROE of -0.33%. Regarding short-term risk, LBPS is less volatile compared to NUVL. This indicates potentially lower risk in terms of short-term price fluctuations for LBPS.Check NUVL's competition here
LBPS vs MRUS Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, MRUS has a market cap of 5.1B. Regarding current trading prices, LBPS is priced at $1.65, while MRUS trades at $67.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas MRUS's P/E ratio is -12.09. In terms of profitability, LBPS's ROE is -1.06%, compared to MRUS's ROE of -0.55%. Regarding short-term risk, LBPS is less volatile compared to MRUS. This indicates potentially lower risk in terms of short-term price fluctuations for LBPS.Check MRUS's competition here
LBPS vs CRSP Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, CRSP has a market cap of 4.9B. Regarding current trading prices, LBPS is priced at $1.65, while CRSP trades at $54.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas CRSP's P/E ratio is -10.06. In terms of profitability, LBPS's ROE is -1.06%, compared to CRSP's ROE of -0.25%. Regarding short-term risk, LBPS is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for LBPS.Check CRSP's competition here
LBPS vs ALKS Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, ALKS has a market cap of 4.9B. Regarding current trading prices, LBPS is priced at $1.65, while ALKS trades at $29.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas ALKS's P/E ratio is 14.37. In terms of profitability, LBPS's ROE is -1.06%, compared to ALKS's ROE of +0.24%. Regarding short-term risk, LBPS is less volatile compared to ALKS. This indicates potentially lower risk in terms of short-term price fluctuations for LBPS.Check ALKS's competition here
LBPS vs TGTX Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, TGTX has a market cap of 4.7B. Regarding current trading prices, LBPS is priced at $1.65, while TGTX trades at $29.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas TGTX's P/E ratio is 77.49. In terms of profitability, LBPS's ROE is -1.06%, compared to TGTX's ROE of +0.29%. Regarding short-term risk, LBPS is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for LBPS.Check TGTX's competition here
LBPS vs CYTK Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, CYTK has a market cap of 4.6B. Regarding current trading prices, LBPS is priced at $1.65, while CYTK trades at $38.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas CYTK's P/E ratio is -7.49. In terms of profitability, LBPS's ROE is -1.06%, compared to CYTK's ROE of +3.09%. Regarding short-term risk, LBPS is less volatile compared to CYTK. This indicates potentially lower risk in terms of short-term price fluctuations for LBPS.Check CYTK's competition here
LBPS vs ALPN Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, LBPS is priced at $1.65, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas ALPN's P/E ratio is -101.52. In terms of profitability, LBPS's ROE is -1.06%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, LBPS is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for LBPS.Check ALPN's competition here
LBPS vs AAPG Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, AAPG has a market cap of 4.4B. Regarding current trading prices, LBPS is priced at $1.65, while AAPG trades at $47.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas AAPG's P/E ratio is -64.62. In terms of profitability, LBPS's ROE is -1.06%, compared to AAPG's ROE of -2.50%. Regarding short-term risk, LBPS is less volatile compared to AAPG. This indicates potentially lower risk in terms of short-term price fluctuations for LBPS.Check AAPG's competition here
LBPS vs KRYS Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, KRYS has a market cap of 4.4B. Regarding current trading prices, LBPS is priced at $1.65, while KRYS trades at $150.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas KRYS's P/E ratio is 30.59. In terms of profitability, LBPS's ROE is -1.06%, compared to KRYS's ROE of +0.15%. Regarding short-term risk, LBPS is less volatile compared to KRYS. This indicates potentially lower risk in terms of short-term price fluctuations for LBPS.Check KRYS's competition here
LBPS vs ACAD Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, ACAD has a market cap of 4.3B. Regarding current trading prices, LBPS is priced at $1.65, while ACAD trades at $25.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas ACAD's P/E ratio is 19.35. In terms of profitability, LBPS's ROE is -1.06%, compared to ACAD's ROE of +0.31%. Regarding short-term risk, LBPS is less volatile compared to ACAD. This indicates potentially lower risk in terms of short-term price fluctuations for LBPS.Check ACAD's competition here
LBPS vs ADMA Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, ADMA has a market cap of 4.2B. Regarding current trading prices, LBPS is priced at $1.65, while ADMA trades at $17.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas ADMA's P/E ratio is 20.94. In terms of profitability, LBPS's ROE is -1.06%, compared to ADMA's ROE of +0.62%. Regarding short-term risk, LBPS is less volatile compared to ADMA. This indicates potentially lower risk in terms of short-term price fluctuations for LBPS.Check ADMA's competition here
LBPS vs TLX Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, TLX has a market cap of 4.2B. Regarding current trading prices, LBPS is priced at $1.65, while TLX trades at $12.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas TLX's P/E ratio is 624.00. In terms of profitability, LBPS's ROE is -1.06%, compared to TLX's ROE of +0.10%. Regarding short-term risk, LBPS is less volatile compared to TLX. This indicates potentially lower risk in terms of short-term price fluctuations for LBPS.Check TLX's competition here
LBPS vs OPT Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, LBPS is priced at $1.65, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas OPT's P/E ratio is -1.52. In terms of profitability, LBPS's ROE is -1.06%, compared to OPT's ROE of +2.60%. Regarding short-term risk, LBPS is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for LBPS.Check OPT's competition here
LBPS vs PCVX Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, PCVX has a market cap of 4.2B. Regarding current trading prices, LBPS is priced at $1.65, while PCVX trades at $32.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas PCVX's P/E ratio is -7.86. In terms of profitability, LBPS's ROE is -1.06%, compared to PCVX's ROE of -0.17%. Regarding short-term risk, LBPS is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for LBPS.Check PCVX's competition here
LBPS vs MRTX Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, LBPS is priced at $1.65, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas MRTX's P/E ratio is -4.82. In terms of profitability, LBPS's ROE is -1.06%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, LBPS is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for LBPS.Check MRTX's competition here
LBPS vs PTCT Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, PTCT has a market cap of 4B. Regarding current trading prices, LBPS is priced at $1.65, while PTCT trades at $50.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas PTCT's P/E ratio is 7.17. In terms of profitability, LBPS's ROE is -1.06%, compared to PTCT's ROE of -0.99%. Regarding short-term risk, LBPS is less volatile compared to PTCT. This indicates potentially lower risk in terms of short-term price fluctuations for LBPS.Check PTCT's competition here
LBPS vs ACLX Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, ACLX has a market cap of 4B. Regarding current trading prices, LBPS is priced at $1.65, while ACLX trades at $71.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas ACLX's P/E ratio is -20.90. In terms of profitability, LBPS's ROE is -1.06%, compared to ACLX's ROE of -0.43%. Regarding short-term risk, LBPS is less volatile compared to ACLX. This indicates potentially lower risk in terms of short-term price fluctuations for LBPS.Check ACLX's competition here
LBPS vs AKRO Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, AKRO has a market cap of 3.9B. Regarding current trading prices, LBPS is priced at $1.65, while AKRO trades at $49.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas AKRO's P/E ratio is -12.92. In terms of profitability, LBPS's ROE is -1.06%, compared to AKRO's ROE of -0.32%. Regarding short-term risk, LBPS is less volatile compared to AKRO. This indicates potentially lower risk in terms of short-term price fluctuations for LBPS.Check AKRO's competition here
LBPS vs ZLAB Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, ZLAB has a market cap of 3.9B. Regarding current trading prices, LBPS is priced at $1.65, while ZLAB trades at $35.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas ZLAB's P/E ratio is -17.52. In terms of profitability, LBPS's ROE is -1.06%, compared to ZLAB's ROE of -0.27%. Regarding short-term risk, LBPS is less volatile compared to ZLAB. This indicates potentially lower risk in terms of short-term price fluctuations for LBPS.Check ZLAB's competition here
LBPS vs RYZB Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, LBPS is priced at $1.65, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas RYZB's P/E ratio is -57.86. In terms of profitability, LBPS's ROE is -1.06%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, LBPS is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for LBPS.Check RYZB's competition here
LBPS vs CBAY Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, LBPS is priced at $1.65, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas CBAY's P/E ratio is -32.81. In terms of profitability, LBPS's ROE is -1.06%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, LBPS is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for LBPS.Check CBAY's competition here
LBPS vs SLNO Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, SLNO has a market cap of 3.6B. Regarding current trading prices, LBPS is priced at $1.65, while SLNO trades at $68.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas SLNO's P/E ratio is -16.25. In terms of profitability, LBPS's ROE is -1.06%, compared to SLNO's ROE of -0.74%. Regarding short-term risk, LBPS is less volatile compared to SLNO. This indicates potentially lower risk in terms of short-term price fluctuations for LBPS.Check SLNO's competition here
LBPS vs MIRM Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, MIRM has a market cap of 3.6B. Regarding current trading prices, LBPS is priced at $1.65, while MIRM trades at $71.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas MIRM's P/E ratio is -59.11. In terms of profitability, LBPS's ROE is -1.06%, compared to MIRM's ROE of -0.25%. Regarding short-term risk, LBPS is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for LBPS.Check MIRM's competition here
LBPS vs PTGX Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, PTGX has a market cap of 3.6B. Regarding current trading prices, LBPS is priced at $1.65, while PTGX trades at $57.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas PTGX's P/E ratio is 78.74. In terms of profitability, LBPS's ROE is -1.06%, compared to PTGX's ROE of +0.08%. Regarding short-term risk, LBPS is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for LBPS.Check PTGX's competition here
LBPS vs MLTX Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, MLTX has a market cap of 3.5B. Regarding current trading prices, LBPS is priced at $1.65, while MLTX trades at $55.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas MLTX's P/E ratio is -20.03. In terms of profitability, LBPS's ROE is -1.06%, compared to MLTX's ROE of -0.42%. Regarding short-term risk, LBPS is less volatile compared to MLTX. This indicates potentially lower risk in terms of short-term price fluctuations for LBPS.Check MLTX's competition here
LBPS vs SWTX Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, LBPS is priced at $1.65, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas SWTX's P/E ratio is -13.78. In terms of profitability, LBPS's ROE is -1.06%, compared to SWTX's ROE of -0.51%. Regarding short-term risk, LBPS is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for LBPS.Check SWTX's competition here
LBPS vs APLS Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, APLS has a market cap of 3.5B. Regarding current trading prices, LBPS is priced at $1.65, while APLS trades at $27.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas APLS's P/E ratio is -15.28. In terms of profitability, LBPS's ROE is -1.06%, compared to APLS's ROE of -1.16%. Regarding short-term risk, LBPS is less volatile compared to APLS. This indicates potentially lower risk in terms of short-term price fluctuations for LBPS.Check APLS's competition here
LBPS vs MTSR Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, MTSR has a market cap of 3.5B. Regarding current trading prices, LBPS is priced at $1.65, while MTSR trades at $33.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas MTSR's P/E ratio is -11.24. In terms of profitability, LBPS's ROE is -1.06%, compared to MTSR's ROE of -0.90%. Regarding short-term risk, LBPS is less volatile compared to MTSR. This indicates potentially lower risk in terms of short-term price fluctuations for LBPS.Check MTSR's competition here
LBPS vs SRRK Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, SRRK has a market cap of 3.4B. Regarding current trading prices, LBPS is priced at $1.65, while SRRK trades at $35.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas SRRK's P/E ratio is -12.15. In terms of profitability, LBPS's ROE is -1.06%, compared to SRRK's ROE of -1.27%. Regarding short-term risk, LBPS is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for LBPS.Check SRRK's competition here
LBPS vs LEGN Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, LEGN has a market cap of 3.3B. Regarding current trading prices, LBPS is priced at $1.65, while LEGN trades at $35.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas LEGN's P/E ratio is -19.98. In terms of profitability, LBPS's ROE is -1.06%, compared to LEGN's ROE of -0.31%. Regarding short-term risk, LBPS is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for LBPS.Check LEGN's competition here
LBPS vs KYMR Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, KYMR has a market cap of 3.2B. Regarding current trading prices, LBPS is priced at $1.65, while KYMR trades at $44.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas KYMR's P/E ratio is -12.64. In terms of profitability, LBPS's ROE is -1.06%, compared to KYMR's ROE of -0.32%. Regarding short-term risk, LBPS is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for LBPS.Check KYMR's competition here
LBPS vs LGND Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, LGND has a market cap of 3.1B. Regarding current trading prices, LBPS is priced at $1.65, while LGND trades at $159.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas LGND's P/E ratio is -39.38. In terms of profitability, LBPS's ROE is -1.06%, compared to LGND's ROE of -0.09%. Regarding short-term risk, LBPS is less volatile compared to LGND. This indicates potentially lower risk in terms of short-term price fluctuations for LBPS.Check LGND's competition here
LBPS vs XENE Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, XENE has a market cap of 3B. Regarding current trading prices, LBPS is priced at $1.65, while XENE trades at $38.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas XENE's P/E ratio is -10.94. In terms of profitability, LBPS's ROE is -1.06%, compared to XENE's ROE of -0.39%. Regarding short-term risk, LBPS is less volatile compared to XENE. This indicates potentially lower risk in terms of short-term price fluctuations for LBPS.Check XENE's competition here
LBPS vs ARWR Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, ARWR has a market cap of 2.9B. Regarding current trading prices, LBPS is priced at $1.65, while ARWR trades at $21.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas ARWR's P/E ratio is -17.76. In terms of profitability, LBPS's ROE is -1.06%, compared to ARWR's ROE of -0.41%. Regarding short-term risk, LBPS is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for LBPS.Check ARWR's competition here
LBPS vs VKTX Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, VKTX has a market cap of 2.9B. Regarding current trading prices, LBPS is priced at $1.65, while VKTX trades at $26.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas VKTX's P/E ratio is -16.88. In terms of profitability, LBPS's ROE is -1.06%, compared to VKTX's ROE of -0.20%. Regarding short-term risk, LBPS is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for LBPS.Check VKTX's competition here
LBPS vs CRNX Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, CRNX has a market cap of 2.9B. Regarding current trading prices, LBPS is priced at $1.65, while CRNX trades at $30.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas CRNX's P/E ratio is -7.54. In terms of profitability, LBPS's ROE is -1.06%, compared to CRNX's ROE of -0.32%. Regarding short-term risk, LBPS is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for LBPS.Check CRNX's competition here
LBPS vs RARE Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, RARE has a market cap of 2.9B. Regarding current trading prices, LBPS is priced at $1.65, while RARE trades at $29.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas RARE's P/E ratio is -5.43. In terms of profitability, LBPS's ROE is -1.06%, compared to RARE's ROE of -2.37%. Regarding short-term risk, LBPS is less volatile compared to RARE. This indicates potentially lower risk in terms of short-term price fluctuations for LBPS.Check RARE's competition here
LBPS vs MORF Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, LBPS is priced at $1.65, while MORF trades at $56.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas MORF's P/E ratio is -14.88. In terms of profitability, LBPS's ROE is -1.06%, compared to MORF's ROE of -0.16%. Regarding short-term risk, LBPS is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for LBPS.Check MORF's competition here
LBPS vs MOR Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, LBPS is priced at $1.65, while MOR trades at $18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas MOR's P/E ratio is -12.64. In terms of profitability, LBPS's ROE is -1.06%, compared to MOR's ROE of -1.84%. Regarding short-term risk, LBPS is less volatile compared to MOR. This indicates potentially lower risk in terms of short-term price fluctuations for LBPS.Check MOR's competition here
LBPS vs NAMS Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, NAMS has a market cap of 2.8B. Regarding current trading prices, LBPS is priced at $1.65, while NAMS trades at $25.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas NAMS's P/E ratio is -15.72. In terms of profitability, LBPS's ROE is -1.06%, compared to NAMS's ROE of -0.25%. Regarding short-term risk, LBPS is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for LBPS.Check NAMS's competition here
LBPS vs KDNY Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, KDNY has a market cap of 2.7B. Regarding current trading prices, LBPS is priced at $1.65, while KDNY trades at $40.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas KDNY's P/E ratio is -12.47. In terms of profitability, LBPS's ROE is -1.06%, compared to KDNY's ROE of -0.41%. Regarding short-term risk, LBPS is more volatile compared to KDNY. This indicates potentially higher risk in terms of short-term price fluctuations for LBPS.Check KDNY's competition here
LBPS vs IMVT Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, IMVT has a market cap of 2.7B. Regarding current trading prices, LBPS is priced at $1.65, while IMVT trades at $15.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas IMVT's P/E ratio is -5.37. In terms of profitability, LBPS's ROE is -1.06%, compared to IMVT's ROE of -0.84%. Regarding short-term risk, LBPS is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for LBPS.Check IMVT's competition here
LBPS vs MYOV Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, MYOV has a market cap of 2.6B. Regarding current trading prices, LBPS is priced at $1.65, while MYOV trades at $26.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas MYOV's P/E ratio is -14.05. In terms of profitability, LBPS's ROE is -1.06%, compared to MYOV's ROE of +0.50%. Regarding short-term risk, LBPS is more volatile compared to MYOV. This indicates potentially higher risk in terms of short-term price fluctuations for LBPS.Check MYOV's competition here
LBPS vs CPRX Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, CPRX has a market cap of 2.6B. Regarding current trading prices, LBPS is priced at $1.65, while CPRX trades at $21.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas CPRX's P/E ratio is 12.78. In terms of profitability, LBPS's ROE is -1.06%, compared to CPRX's ROE of +0.27%. Regarding short-term risk, LBPS is less volatile compared to CPRX. This indicates potentially lower risk in terms of short-term price fluctuations for LBPS.Check CPRX's competition here
LBPS vs KNSA Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, KNSA has a market cap of 2.5B. Regarding current trading prices, LBPS is priced at $1.65, while KNSA trades at $33.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas KNSA's P/E ratio is 675.00. In terms of profitability, LBPS's ROE is -1.06%, compared to KNSA's ROE of +0.01%. Regarding short-term risk, LBPS is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for LBPS.Check KNSA's competition here
LBPS vs VCYT Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, VCYT has a market cap of 2.4B. Regarding current trading prices, LBPS is priced at $1.65, while VCYT trades at $31.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas VCYT's P/E ratio is 91.18. In terms of profitability, LBPS's ROE is -1.06%, compared to VCYT's ROE of +0.02%. Regarding short-term risk, LBPS is less volatile compared to VCYT. This indicates potentially lower risk in terms of short-term price fluctuations for LBPS.Check VCYT's competition here
LBPS vs TARS Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, TARS has a market cap of 2.4B. Regarding current trading prices, LBPS is priced at $1.65, while TARS trades at $57.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas TARS's P/E ratio is -25.00. In terms of profitability, LBPS's ROE is -1.06%, compared to TARS's ROE of -0.32%. Regarding short-term risk, LBPS is less volatile compared to TARS. This indicates potentially lower risk in terms of short-term price fluctuations for LBPS.Check TARS's competition here
LBPS vs PRVB Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, PRVB has a market cap of 2.4B. Regarding current trading prices, LBPS is priced at $1.65, while PRVB trades at $24.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas PRVB's P/E ratio is -16.43. In terms of profitability, LBPS's ROE is -1.06%, compared to PRVB's ROE of +1.33%. Regarding short-term risk, LBPS is more volatile compared to PRVB. This indicates potentially higher risk in terms of short-term price fluctuations for LBPS.Check PRVB's competition here
LBPS vs FOLD Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, FOLD has a market cap of 2.3B. Regarding current trading prices, LBPS is priced at $1.65, while FOLD trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas FOLD's P/E ratio is -63.42. In terms of profitability, LBPS's ROE is -1.06%, compared to FOLD's ROE of -0.20%. Regarding short-term risk, LBPS is less volatile compared to FOLD. This indicates potentially lower risk in terms of short-term price fluctuations for LBPS.Check FOLD's competition here
LBPS vs LBPH Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, LBPH has a market cap of 2.3B. Regarding current trading prices, LBPS is priced at $1.65, while LBPH trades at $59.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas LBPH's P/E ratio is -26.66. In terms of profitability, LBPS's ROE is -1.06%, compared to LBPH's ROE of -0.21%. Regarding short-term risk, LBPS is more volatile compared to LBPH. This indicates potentially higher risk in terms of short-term price fluctuations for LBPS.Check LBPH's competition here
LBPS vs LQDA Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, LQDA has a market cap of 2.3B. Regarding current trading prices, LBPS is priced at $1.65, while LQDA trades at $26.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas LQDA's P/E ratio is -14.75. In terms of profitability, LBPS's ROE is -1.06%, compared to LQDA's ROE of -1.58%. Regarding short-term risk, LBPS is less volatile compared to LQDA. This indicates potentially lower risk in terms of short-term price fluctuations for LBPS.Check LQDA's competition here
LBPS vs APGE Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, APGE has a market cap of 2.3B. Regarding current trading prices, LBPS is priced at $1.65, while APGE trades at $38.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas APGE's P/E ratio is -9.24. In terms of profitability, LBPS's ROE is -1.06%, compared to APGE's ROE of -0.23%. Regarding short-term risk, LBPS is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for LBPS.Check APGE's competition here
LBPS vs CNTA Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, CNTA has a market cap of 2.3B. Regarding current trading prices, LBPS is priced at $1.65, while CNTA trades at $17.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas CNTA's P/E ratio is -9.19. In terms of profitability, LBPS's ROE is -1.06%, compared to CNTA's ROE of -0.56%. Regarding short-term risk, LBPS is less volatile compared to CNTA. This indicates potentially lower risk in terms of short-term price fluctuations for LBPS.Check CNTA's competition here
LBPS vs DICE Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, DICE has a market cap of 2.3B. Regarding current trading prices, LBPS is priced at $1.65, while DICE trades at $47.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas DICE's P/E ratio is -21.91. In terms of profitability, LBPS's ROE is -1.06%, compared to DICE's ROE of +0.56%. Regarding short-term risk, LBPS is more volatile compared to DICE. This indicates potentially higher risk in terms of short-term price fluctuations for LBPS.Check DICE's competition here
LBPS vs DNLI Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, DNLI has a market cap of 2.3B. Regarding current trading prices, LBPS is priced at $1.65, while DNLI trades at $15.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas DNLI's P/E ratio is -5.51. In terms of profitability, LBPS's ROE is -1.06%, compared to DNLI's ROE of -0.41%. Regarding short-term risk, LBPS is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for LBPS.Check DNLI's competition here
LBPS vs AGIO Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, AGIO has a market cap of 2.3B. Regarding current trading prices, LBPS is priced at $1.65, while AGIO trades at $38.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas AGIO's P/E ratio is 3.44. In terms of profitability, LBPS's ROE is -1.06%, compared to AGIO's ROE of +0.43%. Regarding short-term risk, LBPS is less volatile compared to AGIO. This indicates potentially lower risk in terms of short-term price fluctuations for LBPS.Check AGIO's competition here
LBPS vs CELC Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, CELC has a market cap of 2.2B. Regarding current trading prices, LBPS is priced at $1.65, while CELC trades at $52.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas CELC's P/E ratio is -15.11. In terms of profitability, LBPS's ROE is -1.06%, compared to CELC's ROE of -1.50%. Regarding short-term risk, LBPS is less volatile compared to CELC. This indicates potentially lower risk in terms of short-term price fluctuations for LBPS.Check CELC's competition here
LBPS vs IDYA Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, IDYA has a market cap of 2.2B. Regarding current trading prices, LBPS is priced at $1.65, while IDYA trades at $25.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas IDYA's P/E ratio is -6.54. In terms of profitability, LBPS's ROE is -1.06%, compared to IDYA's ROE of -0.31%. Regarding short-term risk, LBPS is less volatile compared to IDYA. This indicates potentially lower risk in terms of short-term price fluctuations for LBPS.Check IDYA's competition here
LBPS vs IBRX Comparison August 2025
LBPS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LBPS stands at 0. In comparison, IBRX has a market cap of 2.2B. Regarding current trading prices, LBPS is priced at $1.65, while IBRX trades at $2.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LBPS currently has a P/E ratio of N/A, whereas IBRX's P/E ratio is -4.81. In terms of profitability, LBPS's ROE is -1.06%, compared to IBRX's ROE of +0.61%. Regarding short-term risk, LBPS is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for LBPS.Check IBRX's competition here